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The envelope glycoprotein of the human immunodeficiency virus (HIV) utilizes CD4 as a receptor and CCR5 and/or CXCR4
as coreceptor to gain entry into the cell. The CCR5-tropic viruses, observed early in infection, could be important in
transmission and the CXCR4-tropic viruses, observed late, may play an important role in disease progression. Viruses from
40 HIV-positive, asymptomatic or symptomatic individuals in India were isolated. Of 40 isolates 39 used CCR5. Thirty-three
isolates were subtype C, 3 isolates were subtype A, and 4 isolates were HIV-2. Only 1 HIV-2 isolate, from a symptomatic
individual, was dualtropic. Therefore, a majority of isolates from India belonged to subtype C and all the isolates utilized CCR5
exclusively irrespective of HIV disease status. © 2000 Academic Press
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lIntroduction. The human immunodeficiency virus type
1 (HIV-1) uses chemokine receptor CCR5 and/or CXCR4
as the major coreceptor along with CD4 to gain entry into
cells. Coreceptor usage came into prominence with the
discovery of refractoriness to HIV infection in individuals
homozygous for the d-32 mutation in the CCR5 gene (1,
). Coreceptor usage has been shown to correlate with
he syncytium-inducing phenotype of the virus. The non-
yncytium-inducing viruses use CCR5 while the syncyti-
m-inducing (SI) viruses use multiple coreceptors, either
ne or several of the other coreceptors, i.e., CXCR4,
CR3, CCR2B, CCR8, GPR15 (BOB), STRL33 (Bonzo), and
X3CR1, in addition to CCR5 (3). HIV-2 isolates have also
een shown to be promiscuous in their coreceptor usage
4). Several studies have shown that virus isolates from
IV-1-positive individuals early in infection are non-syn-
ytium inducing or CCR5-tropic (R5 viruses) while iso-
ates obtained late in the course of disease are syncyti-
m-inducing or CCR5/CXCR4-tropic (R5/X4 viruses) (5).
solates from AIDS patients were also reported to use
XCR4, CCR3, CCR2B, CCR4, and BOB in addition to
CR5 (6). Several reports have thus shown an associa-
ion between disease progression and switch in core-
eptor usage. In an ex vivo study, CXCR4 specificity was
hown to be a causal factor in CD41 T cell depletion,
upporting the hypothesis that usage of CXCR4 acceler-
tes immunodeficiency (7).
1 To whom correspondence and reprint requests should be ad-
t
r
ressed at 20-A Dr. Ambedkar Road, Pune 411001, India. Fax: 91-20-
22669. E-mail: cdayaraj@hotmail.com.
253In this study 40 HIV strains isolated from HIV-infected
ndividuals in India were tested for their coreceptor us-
ge. The individuals were classified as symptomatic or
symptomatic based on their clinical presentation. The
D41 T cell counts were also determined in 20 blood
amples. The subtype of all the isolates was determined
y the heteroduplex mobility assay (HMA). The study
as undertaken to assess whether the coreceptor usage
f viruses isolated from patients early in the course of
nfection differs from that of viruses isolated from pa-
ients who had various opportunistic infections indicating
evelopment of AIDS.
Results. Profile of HIV-positive individuals. A total of 40
rimary isolates were obtained from blood collected
rom HIV-positive individuals residing in different parts of
ndia. The majority of the isolates were from western
ndia—Maharashtra (n 5 25), Goa (n 5 6), Gujarat
n 5 2) and others were from South India (n 5 3), North
ndia (n 5 3), and East India (n 5 1). The mode of
ransmission was largely heterosexual. Of the 40 cases,
nly 3 had acquired the infection through blood transfu-
ion and 1 by vertical transmission. Of the 40 HIV-posi-
ive individuals, 37 were in the age range of 22–47 with
median of 32. Of the remaining 3, 2 were above the
ange, ages 52 and 63, and 1 was 6 years of age.
Classification of HIV-Positive Individuals. The absolute
D41 T cell count was determined for 20/40 individuals,
ho were classified according to the CDC AIDS surveil-
ance case definition—1993 (8) (Table 1). Of the 20 pa-
ients, 7 were in the early stage of HIV infection, while the
emaining 13 were in the advanced stage of HIV disease
0042-6822/00 $35.00
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3254 RAPID COMMUNICATIONor AIDS. Of those in the advanced HIV disease stage, 5
had CD41 T cell counts of fewer than 50 cells/mm3, 4 had
50–100 cells/mm3, while 4 had between 100 and 200
cells/mm3.
Of the patients in whom CD41 T cell counts were not
done, 6 were asymptomatic and 1 had an infection not
particularly related to AIDS. Of the remaining 13, 4 had
pulmonary tuberculosis, 4 had tubercular lymphadenitis,
1 had tubercular cold abscess, and 4 had HIV-related
conditions.
Subtyping of Isolates by HMA. Four of the 40 isolates
were HIV-2 by serological tests (9). The 36 HIV-1 isolates
were subtyped using HMA (10) (Table 2). Three isolates
belonged to subtype A of which 2 were genotyped as A3
(prototype Rwanda) and 1 as A1 (prototype Rwanda). The
rest of the 33 HIV-1 isolates belonged to subtype C. On
further genotyping, 25 had closest homology to C3 (pro-
totype India/South Africa), 4 were determined to be C2
(prototype Zambia), and 1 was determined to be C1
(prototype Malawi) genotype. Thus a majority of HIV-1
isolates belonged to subtype C (33/36).
T
HIV Disease Staging (CDC AIDS Surveillance Cas
CDC AIDS disease
case stage n ,50
Early stage
A1 1 Nil
A2 2 Nil
B1 2 Nil
B2 2 Nil
Late stage (AIDS)
A3 2 Nil
B3 4 2
C3 7 3
T
Subtype and Corecept
Symptomatic
Subtype
(genotype)
No. of
patients
Coreceptor
use
HIV-1
A (A1) 1 CCR5
(A3) 1 CCR5
C (C1) 1 CCR5
(C2) 4 CCR5
(C3) 21 CCR5
(NDa) 3 CCR5
HIV-2 1 CCR5
1 CCR5/CXCR4a ND—not done.Coreceptor Usage of Isolates. The coreceptor usage of
the HIV-1/2 isolates was determined using the infectivity
assay in GHOST cells expressing either CXCR4 or CCR5
(11). The mean number of fluorescent cells in uninfected
GHOST–CXCR4 was 16 6 12 and in GHOST–CCR5 cells,
it was 13 6 8, based on 12 observations each. The mean
value obtained in uninfected cultures 1 3 SD was con-
sidered the negative cut-off. Thus values of more than 50
fluorescent cells/15–20,000 events were considered pos-
itive for virus infectivity. Figure 1 shows the representa-
tive scattergrams of GHOST–CXCR4 and GHOST–CCR5
cells infected with dual-, CXCR4-, and CCR5-tropic vi-
ruses. The laboratory-adapted strains of HIV-1, RF, IIIB,
and MN were used to standardize the infectivity assay in
GHOST cells. While the RF and IIIB strains infected only
GHOST–CXCR4 cells, the MN strain showed 1% infectiv-
ity in GHOST–CCR5 cells, against 24.5% in GHOST–
CXCR4 cells. The percentage of infected cells with pri-
mary isolates varied from 0.8 to 65%.
Of the symptomatic individuals, 32/33 virus isolates
used CCR5 exclusively (Table 2). Twenty of the 33 symp-
nition, 1993) and CD41 T Cell Counts of Patients
CD41 T cell count (cells/mm3)
0 100–200 200–500 .500
Nil Nil 1
Nil 2 Nil
Nil Nil 2
Nil 2 Nil
2 Nil Nil
1 Nil Nil
1 Nil Nil
ge of the HIV Isolates
Asymptomatic
Genotype
No. of
patients
Coreceptor
use
A (A3) 1 CCR5
C (C3) 4 CCR5
HIV-2 2 CCR5ABLE 1
e Defi
50–10
Nil
Nil
Nil
Nil
Nil
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255RAPID COMMUNICATIONtomatic cases had CD41 T cell counts done. Of these 13
ad counts of ,200 cells/mm3 and thus would have
been expected to have CXCR4-tropic viruses. Of these, 6
individuals had tuberculosis infections. The only dual-
tropic isolate was from an HIV-2-infected individual. The
HIV-2 status of this individual was based on immunoblot
results. This was confirmed by PCR amplification of the
env gene using HIV-2-specific primers (9). The isolate
showed 50% infectivity on GHOST–CXCR4 cells versus
7.3% on GHOST–CCR5 cells. The virus isolates from the
7 asymptomatic individuals were all CCR5-tropic.
Discussion. India, compared to any other country, is
projected to have the largest burden of HIV infections. In
a study of the isolates from Pune, India, 96% of the
isolates were subtype C of which 66% were designated
C3 genotype with maximum homology to the Indian C3
reference strain (10). In the present study 91.7% of the
HIV-1 isolates were subtype C. Subtype C is also pre-
dominant in most recent HIV-1 epidemics worldwide (12).
Recently it was reported that patients infected with sub-
type C isolates developed AIDS earlier than patients
infected with subtype A virus (13). The presence of three
or four NF-kB sites in subtype C viruses is thought to
improve viral transcription (14) and thereby increase the
pathogenicity of the virus.
Several studies have shown that broadening of the
coreceptor usage profile of HIV-1 isolates may be asso-
ciated with progression of disease to AIDS; 50% of the
isolates from AIDS cases showed multiple coreceptor
FIG. 1. Scattergrams derived from the FACScan analysis showing
HOST–CXCR4 and GHOST–CCR5 cells infected with different HIV-1
solates. The region R1 delineates the fluorescence-positive infected
ells. (A) The dualtropic HIV-2 primary isolate, (B) a CCR5-tropic HIV-1
rimary isolate, and (C) the CXCR4-tropic laboratory-adapted RF strain.usage (3). A study using sequential isolates from four
rapid progressors, six late progressors, and three long-
p
mterm nonprogressors showed that the switch from CCR5
usage to multiple coreceptor usage occurred in all four
rapid progressors and three of six late progressors (6).
The emergence of multiple coreceptor-utilizing variants
preceded CD4 depletion to ,200 million/L and corre-
lated with development of AIDS.
In the present study coreceptor usage of isolates from
asymptomatic and symptomatic HIV-infected individuals
from India was determined. HIV-infected individuals with
tuberculosis were also classified as AIDS cases as per
the CDC AIDS case definition. Persons having a disorder
indicative of the progression toward AIDS were treated
as symptomatic.
With the 33 subtype C viruses analyzed in this study,
we observed no difference in the coreceptor usage of
isolates from HIV-positive individuals at both ends of the
disease spectrum, with CD41 T cell counts as low as 23
or as high as 905. Analysis of the V3 sequence of Indian
isolates reported so far (15–17) revealed that the serine
at position 11, which is essential for CCR5 usage, was
present in all the strains and two arginine residues at
positions 8, 11, and/or 18 needed for CXCR4 usage (18)
were absent in all strains. The predominance of CCR5-
using isolates has been recently reported for isolates
from Ethiopia. A low frequency (6%) of SI viruses using
CXCR4 and/or CCR5 and/or CCR3 was observed in 48
Ethiopian AIDS patients by Abebe et al. (19). In another
study from Ethiopia, Bjorndal et al. (20) studied corecep-
tor usage in 9 AIDS patients. All isolates were classified
as subtype C and all were found to use CCR5 as the
coreceptor. A lower representation of CXCR4 usage was
also reported in subtype C isolates from Malawi (21). In
a study using biological clones of HIV-1 isolated both
early and late from progressors and long-term survivors
with wild-type or mutant CCR5/CCR2b genotypes, all the
clones were restricted to the use of CCR5 (22), thus
leading to the conclusion that an expanded coreceptor
repertoire is not a prerequisite for progression in the
clinical course of disease.
There have been several recent reports on the signif-
icance of CCR5 in viral pathogenesis in vivo. The natural
knockout d-32 mutation in CCR5 was shown to confer
resistance to infection (1, 2). The promoter allele of CCR5
P1 was shown to be associated with rapid development
of AIDS. Genetic association analysis of five cohorts of
people with AIDS revealed that 10–17% of patients who
developed AIDS within 312 years of HIV infection were
omozygous for CCR5P1/P1 (23). Isolates from cases of
ementia were shown to infect microglia, using predom-
nantly CCR5 (24). Subtype C viruses predominantly oc-
ur in developing countries, where HIV-infected individ-
als are exposed to a larger load of communicable
nfections. Up regulation of CCR5 on macrophages in-
ected with Mycobacterium tuberculosis has been re-
orted (25). In human-PBL-SCID mice R5 strains were
ore pathogenic when the human cells exhibited
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256 RAPID COMMUNICATIONmarked activation, 2 weeks after hu-PBL transfer (26). It
has been reported that activation of circulating T lym-
phocytes down regulates expression of CXCR4 and thus
interferes with propagation of X4 HIV strains (27). The
superantigen, staphylococcal enterotoxin A, induced a
marked decrease in expression of CXCR4 in activated
cells positive for CD25. This could be a contributing
factor in developing countries to the nonemergence of X4
viruses or it could be a characteristic of solely subtype C
viruses.
This is the first report from India on coreceptor utiliza-
tion by HIV isolates obtained from symptomatic and
asymptomatic individuals, establishing an exclusive
prevalence of CCR5-tropic viruses in the late stage of
HIV-1 infections in the subcontinent. The findings thus
assume importance in HIV management especially in the
light of a recent report. Analysis of the evolution of virus
diversity in HIV disease led to the conclusion that initia-
tion of HAART before the transient appearance of X4
isolates may be more beneficial (28). Therefore, further
studies need to be undertaken to study the evolution of
HIV diversity in subtype C virus infections in the subcon-
tinent and its implications.
Materials and Methods. Virus isolates. A total of 40
primary HIV-1 or HIV-2 isolates were used in the study.
The isolates were from patients who resided in different
parts of India. HIV-1 strains MN, IIIB, and RF were ob-
tained from the Johns Hopkins School of Medicine.
Cells. Peripheral blood mononuclear cells (PBMCs)
and SupT1 cells were cultured in RPMI 1640 with 20 and
10% FBS, respectively. The PHA-P-stimulated PBMC cul-
tures were supplemented with 5 IU/ml interleukin-2.
GHOST-clone 3 cells expressing either CCR5 or CXCR4
were obtained from Dan Littman (New York University
Medical Center). The GHOST cells are human osteosar-
coma cells genetically manipulated to express CD4 and
one of the coreceptors with green fluorescent protein
(GFP) as the reporter gene driven by the HIV-2 promoter.
The GHOST cells were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% FBS, Gene-
ticin (200 mg/ml), hygromycin (25 mg/ml), and puromycin
(1 mg/ml). The cultures were maintained at 37°C in a 5%
CO2-containing, humidified incubator.
Collection of Sample. Samples were collected from
ndividuals after obtaining their consent and anonymity
as maintained throughout. Blood was collected by ve-
ipuncture into Vacutainers containing EDTA. The spec-
mens were transported to NARI, Pune, and PBMCs were
solated within 48 h. The relevant demographic and clin-
cal data were obtained at the time of sample collection.
Determination of CD4 Count. An aliquot of the blood
ample was directly used for determining the lymphocyte
1rofile. The absolute CD4 T cell count was estimated on
he FACSort (Becton–Dickenson) with the Simulset soft-
o
ware using monoclonal antibody panel consisting of anti-
D45/CD14, anti-1/2 anti-CD3, and anti-CD4 antibodies.
Determination of the HIV Disease Status. The CDC
IDS Surveillance Case Definition, 1993 (8), was used to
tage HIV disease status in 20 cases for whom CD41 T
ell counts were determined. In the remaining 20 cases
he HIV-infected individuals were assessed for any HIV-
elated disorder and then classified as symptomatic or
symptomatic.
Virus Isolation. Viruses were isolated as described by
ulkarni et al. (9). Blood was collected from HIV-seropos-
tive individuals and the PBMCs were separated on Fi-
oll–Hypaque. The patient’s lymphocytes were cocul-
ured with PHA-P-stimulated lymphocytes from HIV-neg-
tive donors in the presence of interleukin-2 (5 IU/ml) for
8 days. Fresh PHA-P-activated, heterologous, lympho-
ytes were added to the culture every week. Culture
upernatants were collected at intervals of 3–4 days and
tored at 270°C. Presence of HIV-1 p24 antigen, deter-
ined by ELISA (Organon Teknika, NL), was considered
n indicator of virus replication.
Determination of the Subtype by HMA. HIV-1 subtyping
as carried out as described by Gadkari et al. (10).
Briefly, DNA was extracted from PBMCs using either the
Isoquick DNA extraction kit (Orca Research Laborato-
ries, U.S.A.) or the QIAamp DNA purification kit (Qiagen,
U.S.A.). A region of the HIV-1 envelope (env) gene, in-
cluding V3, V4, and V5, was amplified using two rounds
of PCR. A 5-ml sample from the nested PCR product of
ach sample was mixed with 5 ml of individual plasmid
PCR products representing reference strains of subtypes
A1, A3, B2, C1, C2, C3, and E2 (obtained from the NIH
AIDS Research and Reference Reagent Program). To
each sample 1.1 ml of HMA buffer (100 mM NaCl, 10 mM
Tris, pH 7.2, 2 mM EDTA) was added, and the sample
was denatured at 94°C for 2 min and reannealed by
quick chilling on ice. The resultant homo- and heterodu-
plexes formed between sample and reference strains
were separated by polyacrylamide (5%) gel electrophore-
sis under nondenaturing conditions at 250 V for 3 h. The
gels were then stained with ethidium bromide for 1 h.
The homoduplexes showed the fastest mobility. The
sample/reference heteroduplex which migrated closest
to the corresponding homoduplex determined the sub-
type designation. Some of the samples were further
analyzed to determine the genotype within the subtype.
Infectivity Assay to Determine Coreceptor Usage.
The method followed was as described by Cecilia et
al. (11). Briefly, 70% confluent monolayers of GHOST
cells expressing either CCR5 or CXCR4 were infected
with virus stocks diluted 1:2 in the presence of 8 mg/ml
EAE-dextran (Sigma). Virus was allowed to adsorb
vernight. Residual virus was removed; the cell sheet
as washed and fresh medium containing 10% FBS
t
n
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257RAPID COMMUNICATIONwas added. Cells were harvested on day 3 or 4 postin-
fection, the day of virus addition being considered day
0. The infected cells were resuspended using 1 mM
EDTA and fixed with 2% formaldehyde. The cells were
then analyzed with the FACSort flow cytometer. The
live cells were gated on the basis of forward and side
scatter. The number of infected cells was determined
by using a scattergram of fluorescence versus forward
scatter after setting the gates with uninfected cells
(Fig. 1). A total of 15–20,000 cells were scored. The
mean number of fluorescent cells in the uninfected
cell cultures 1 3 SD was considered the cut-off value
and cultures with values above the cut-off were con-
sidered positive for virus growth.
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